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A  form of amyloidosis occurring in a  variety of chronic inflammatory diseases  is 
caused  by the  deposition  in  tissues  of a  fibrillar  protein  called  amyloid  A  protein 
(AA). t  Primary  structure  analyses  of AA  from  tissues  of a  patient  with  familial 
Mediterranean  fever (1) and from a  patient  with rheumatoid arthritis  (2)  have been 
described.  In  each  case,  AA was  reported  to  be  a  76-residue  single-chain  protein, 
although there are 9 discrepancies in the published sequences. 
A  protein that is antigenically and chemically related to AA has been identified in 
the serum of normals (3) and in relatively high concentrations in a number of disease 
states (4-7). This acute-phase reactant, designated serum AA (SAA), has an apparent 
molecular  weight  of 11,000-14,000  (8-10).  SAA is  less well-characterized  than  AA, 
but partial  sequence studies have demonstrated  a  high degree of homology between 
SAA and AA in their NH2-terminal  regions (11,  12).  Benditt  and Eriksen's discovery 
(13),  confirmed  by Skogen  et  al.  (14),  that  SAA is  transported  in  association  with 
plasma  high-density lipoproteins  (HDL)  has greatly facilitated  the  purification  and 
characterization of SAA. We have isolated SAA from the HDL of two normals after 
etiocholanolone-induced  inflammation  (15)  and from the HDL of five patients,  two 
of whom  had  secondary  amyloidosis.  Six  polymorphic  forms  of SAA  have  been 
identified. 
Materials  and Methods 
Sources of SAA.  Written,  informed  consent was obtained  from study subjects.  300  ml  of 
plasma  was obtained  from two male  volunteers  before and  48  h  after  deep  intramuscular 
injection of etiocholanoione, 3 mg/kg body wt  (15). Plasma was also obtained from patients 
with Wegener's granulomatosis, Waldenstr6m's macroglobulinemia, Goodpasture's syndrome, 
and  systemic lupus  erythematosus.  A  50-yr-old man  with juvenile  rheumatoid  arthritis  or 
ankylosing spondylitis (HLA B27 phenotype)  donated plasma after etiocholanolone-induced 
inflammation. 
Preparation ofApolipoprotein  (Apo) HDL.  HDL were isolated by preparative uhracentrifuga- 
tion (16) in a  Beckman L5-75 uhraeentrifuge  (Beckman Instruments, Inc., Spinco Div., Palo 
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Alto, Calif.).  Plasma  was adjusted  to a  solvent  density  of 1.080  g/ml  with  solid  KBr and 
centrifuged in a  Beckman 60 Ti  rotor for 20  h  at  10°C and  55,000  rpm  (4.7  ×  106 g/min 
average). Supernatant and infranatant fractions were recovered by tube slicing. The density of 
the infranatant fraction was adjusted to 1.21 g/ml and centrifuged at 59,000 rpm for 24 h (6.1 
×  106 g/min average). The HDL recovered in the supernatant fraction were recentrifuged once 
in a 40 rotor for 48 h at 40,000 rpm (5.1 ×  106 g/min average), dialyzed against 0.15 M  NaC1 
and 2 mM EDTA, and brought to a protein concentration of ~20 mg/ml by dehydration in 
dialysis sacks coated with Aquacide-IIA (Calbiochem-Behring Corp., American Hoescht Corp., 
San  Diego, Calif.).  HDL were  delipidated  with  methanol:diethyl  ether  (1:3)  as  previously 
described (17). 
Column Chromatography.  Apo HDL were initially fractionated on 2.0 ×  140-cm columns of 
Sephadex G-100, Sephacryl S-200, or Sepharose A (0.5 M) (considered preferable) eluted with 
5 M  guanidine-HCl. Rechromatography of the low molecular weight (10,000-15,000) fraction 
on the same column was routinely performed before undertaking additional purification.  15- 
mg aliquots of the SAA-rich fractions were applied to 1.2 X 50-cm columns of DEAE-cellulose 
equilibrated  with 0.01  M  Tris-HCl  6 M  urea,  pH 8.2.  Consecutive 500-ml linear gradients, 
0.01-0.075 M  and 0.075-0.2 M Tris-HC1 were required to optimally separate and completely 
elute all of the SAA and C-apo applied to the columns. The urea was deionized by passage over 
a  Rexyn  300  column  (Fisher  Scientific  Co.,  Pittsburgh,  Pa.)  immediately  before use,  and 
chromatography was carried out at 4°C to prevent carbamylation (18). Approximately 60% of 
the protein applied to the DEAE columns was recovered. 
Characterization of SAA.  Protein concentrations were determined by the Lowry method (19). 
SAA concentrations were estimated by a solid-phase radioimmunoassay with plastic microti- 
tration plates coated with affinity-purified antibodies to AA (15). Lyophilized samples for assay 
were treated with  10% formic acid at 37°C for 18 h before radioimmunoassay (20). Chroma- 
tography fractions were analyzed by anionic (21) and cationic (22) polyacrylamide gel electro- 
phoresis and by Ouchterlony double diffusion. Sodium dodecyl sulfate (SDS)-polyacrylamide 
gel electrophoresis (23) and Ferguson plots (24) were used for molecular weight estimations. 
Amino acid analyses were performed on a Beckman 119 CL amino acid analyzer with a single- 
column system (25). Proteins were hydrolyzed in sealed, evacuated tubes with either 6 N HC1 
for 24 h or in 4 N methane sulfonic acid for 20 h. Cysteic acid was determined after performic 
acid  oxidation  (26).  Carboxypeptidases  A  and  B  were  used  for  COOH-terminal  residue 
identification  and  sequence  analysis  (27).  Sequential  Edman  degradations  were  performed 
manually as described by Peterson et  al.  (28) except  that  the thiazolinone derivatives were 
extracted  with  butylacetate.  Free  amino  acids  were  regenerated  by  hydrolysis  in  sealed 
evacuated  tubes  with  either  hydriodic  acid  or  0.2  N  NaOH  and  0.1  M  dithionite  (29). 
Neuraminidase digestion was performed as described by Morell et al.  (30), and polyacrylamide 
gel bands were qualitatively assessed for carbohydrate with the periodate-Schiff stain (31). 
Results 
Plasma  was  obtained  from  two  young  men  before  and  after  etiocholanolone 
injection.  Local inflammation,  fever, and leukocytosis occurred in both subjects  (15). 
The concentrations  of AA-equivalent  protein  (herein  referred  to as  SAA)  were  1:31 
and 249 #g/ml in the plasma obtained 48 h  after etiocholanolone administration.  A 
plasma SAA level of 175/~g/ml was induced several months later when one of these 
subjects received two consecutive injections of etiocholanolone in a  3-d period. SAA  + 
(>30 #g/ml) plasma was also obtained from patients with Wegener's granulomatosis, 
Waldenstr/Jm's macroglobulinemia, systemic lupus erythematosus, and Goodpasture's 
syndrome. Plasma from a subject with juvenile rheumatoid arthritis was studied after 
etiocholanolone-induced  inflammation.  The patients  with systemic lupus erythema- 
tosus  and juvenile  rheumatoid  arthritis  both  had  biopsy-proven amyloidosis of the 
AA type,  as shown  by histochemical  sensitivity  to potassium  permanganate  before 
staining with Congo red  (32).  Plasma concentrations of SAA ranged from 43 to  139 I,.  I,.  BAUSSERMAN,  P.  N.  ItERBERT,  AND  K.  P.  W..J.  McADAM  643 
#g/ml.  40-65%  of the SAA proteins was recovered in  the HDL  density range  (1.080 
<  density <  1.21  g/ml). 
HDL  from plasma obtained both before and after etiocholanolone-induced inflam- 
mation  were  delipidated  with  organic  solvents  and  fractionated  on  a  column  of 
Sephadex G-100 eluted with 5  M  guanidine-HCl  (Fig.  1).  The void-volume fraction 
contained only small quantities of protein. Apo A-I (Mr ~  28,000),  the major HDL 
apoprotein, was the principal component of peak 2  (Fig.  1, insert) and the third peak 
contained primarily apo A-II (Mr ~  15,700). An obvious increase in the proportion of 
l"lc;.  1.  Comparison ofSephadex G-100 elution profiles ofapo HDL obtained from a normal donor 
after (A) and before (B) etiocholanolone-induced inflammation.  20 mg of protein was applied to a 
2.5 ×  140-cm column eluted with 5 M guanidine-HCl,  and the indicated pools were analyzed by 
anionic (21) polyacrylamide gel electrophoresis (inserts). 644  HETEROGENEITY OF  HUMAN  SERUM  AMYLOID A  PROTEINS 
protein in fraction 4 was evident in the SAA-rich apo HDL (Fig.  1 A). More than 85% 
of the  SAA  protein  recovered  eluted  in  this  fraction.  When  the  same  volunteer 
received two injections of etiocholanolone, the proportionate increase in peak 4 was 
even more striking  (Fig.  2), and  the fraction  4 proteins comprised 24% of the total 
protein recovered from the column. 
The HDL apo from all of the patients with SAA +  plasma were fractionated on 
Sephacryl S-200 eluted with guanidine-HCl.  The elution profiles of apo HDL from 
patients  with Goodpasture's syndrome  (Fig.  3A)  and Waldenstr6m's  macroglobuli- 
hernia (Fig. 3 B) suggested reduction of the apo A-II content (peak 3), whereas the low 
molecular weight  protein  peaks  (fraction  4),  which  contained  24-27%  of the  total 
protein, were again proportionately large. 
Anionic polyacrylamide gel electropherograms of the fraction 4 proteins from the 
two normals receiving etiocholanolone (Fig. 4 A) and from all five patients (Fig. 4 B) 
clearly demonstrated that this fraction contained several proteins not usually identi- 
fiable in SAA- apo HDL. The proteins that normally comprise this peak include that 
provisionally  designated  "D-2"  by  Lim  et  al.  (33),  and  the  well-characterized  C- 
apoproteins.  The quantities  of C-apoproteins visualized varied considerably among 
the study subjects. They were quite distinct in the apo HDL from the subjects with 
juvenile rheumatoid arthritis  and systemic lupus erythematosus and present in trace 
concentrations in the apo HDL of the patient with Waldenstr6m's macroglobulinemia 
and  the  volunteer  who  received  two  injections  of etiocholanolone  (Fig.  4B,  E-2). 
FIO,  2.  Fractionation of apo HDL from a  volunteer who had received two injections of etiocho- 
lanolone, 0.3  mg/kg. A 2.5  X  140-cm  column of Sephadex G-100 was eluted with 5 M  guanidine- 
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Fxo. 3.  Sephacryl S-200 chromatography  of the SAA +  apo HDL from patients with Walden- 
str6m's  macroglobulinemia  (A) and Goodpasture's  syndrome  (B). A 2.0  ×  140-cm column  was 
eluted with guanidine-HCl. Column fractions were pooled as indicated, and their apoproteins were 
visualized by anionic polyacrylamide gel eleetrophoresis (21). 
Several protein species of low electrophoretic mobility were  prominent  in  all SAA- 
rich  fractions.  The  relative  intensities  (and  presumably  concentrations)  of  these 
protein bands were not the same in each patient. It is noteworthy that  the quantita- 
tively major SAA proteins had mobilities indistinguishable from apo A-I and apo A- 
II in the electrophoretic system employed. 
Because the fraction 4  proteins were found by Ouchterlony double diffusion to be 646  HETEROGENEITY OF  HUMAN SERUM AMYLOID A PROTEINS 
Fig. 3 B. 
contaminated with apo A-I and apo A-II, they were rechromatographed on Sephadex 
G-100  before further  purification  was attempted.  Apo  C-I, which  elutes  after SAA 
from  Sephadex  G-100  and  Sephacryl  S-200,  was  also  completely  removed  in  the 
rechromatography  step.  Separation  of the  SAA  and  remaining  C-apoproteins  was 
then accomplished by DEAE chromatography. Six polymorphic forms of SAA were 
isolated from the fraction 4 proteins of the normal volunteers injected with etiocho- 
ianolone (Fig. 5 A) and from the patient with Waldenstr6m's macroglobulinemia (Fig. 
5 B).  All  of these were eluted  by the  gradient  between  apo C-I and  apo C-II. The FIG.  4.  (A)  Comparison  of the  low  molecular weight  fractions of apo  HDL  from  an  SAA  - 
preparation (N 1 Fx-4) with those from the two normals after etiocholanolone-induced inflammation 
(E-1 and E-2) and with unfractionated normal apo HDL (apo HDL). Electrophoresis was performed 
in  gels  of  7.5% acrylamide  monomer  at  pH  9.4  in  8  M  urea  (21).  (B)  Polyacrylamide  gel 
electrophoretograms  of  the  low  molecular  weight  fractions  of  apo  HDL  from  patients  with 
rheumatoid  arthritis  (RA),  systemic  lupus  erythematosis  (SLE),  Goodpasture's  syndrome  (G), 
Wegener's granulomatosis (W), and Waldenstr6m's macroglobulinemia (WM). 
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FIC.  5.  DEAE-cellulose chromatography  ofthe low molecular weight fractions ofthe SAA-enriched 
apo HDL  from a  normal subject after two injections of etiocholanolone  (A) and from a  patient  with 
Waldenstr~Jm's macroglobulinemia  (B). 
relative amounts of the SAA species were not identical, but the major forms eluting 
in the fourth and fifth peaks comprised between 63 and 68% of the total SAA in all 
patients and normals studied. Immunoassay indicated that SAA accounted for >95% 
of the  protein  in  peaks  1-5  and  somewhat  less  in  peak  6.  Homogeneity was  also 
assessed  by polyacrylamide gel  electrophoresis in  anionic,  cationic, and  SDS-poly- 
acrylamide gel electrophoresis systems. In SDS (not shown) and at pH =  2.5 (Fig. 6) 
the six SAA polymorphs were indistinguishable. Consistent with their order of elution 
from DEAE, however, all had different mobilities in the anionic system (Fig. 6). All 
six  fractions were  quite  pure  except  for peak  6,  which  contained  an  unidentified 
contaminant. 
The  amino  acid  compositions  (Table  I)  of the  six  SAA  forms were  remarkably 
similar. None contained cysteine, and threonine could be confidently quantified only 
in  fraction  1.  All SAA polymorphs were rich in glycine, alanine, and arginine and 
were relatively deficient in glutamic acid/glutamine and leucine residues on compar- 
ison with the other apo (34). 
The  chemical  bases  of the  SAA  polymorphism  have  not  yet  been  completely L.  L.  BAUSSERMAN, P.  N.  HERBERT, AND K.  P.  W. J.  McADAM  649 
F~¢~.  6.  Polyacrylamide  gel electrophoresis of the SAA-containing DEAE fractions. Top panel: 
Electrophoresis in an anionic system (21) with 7.5% acrylamide and 8.0 M urea. Bottom panel: 
Analysis in a cationic system (22) with 5.0% acrylamide and 8.0 M urea. 
defined. Incubation with neuraminidase did not alter the electrophoretic mobilities of 
any  of the  SAA polymorphs, and  none stained  with  the  periodate-Schiff reagent. 
Carboxypeptidase  A  released  primarily  tyrosine  from  all  DEAE  fractions.  Timed 
carboxypeptidase A plus B digestions indicated the terminal sequence COOH-tyr-lys- 
phe-. Molecular weight estimates, calculated on the basis of tyrosine released, ranged 
from 11,100  to  11,900, consistent with the observed elution volumes from columns of 
Sephadex G-100. SDS-polyacrylamide gel electrophoresis demonstrated that SAA was 
smaller than iysozyme (Mr -  14,300)  and slightly larger than apo C-II (Mr ~  9,000). 
Because SDS-polyacrylamide gel electrophoresis does not provide good size discrimi- 
nation at under 15,000 mol wt, mobilities of the various forms of SAA were compared 
on polyacrylamide gels with acrylamide monomer concentrations varying from 7.5 to 
20%  (24).  All  of the  polymorphic forms  of SAA had  indistinguishable  mobilities. 
Amino-terminal sequence analyses have been performed on the two major forms of 650  HETEROGENEITY  OF  HUMAN  SERUM  AMYLOID  A  PROTEINS 
TABLE  I 
Amino Acid Composition  * of SAA Proteins Purified by DEAE Chromatography 
DEAF~ pool  l:~  2§  311  4~  51t  6¶ 
rnol/ lO0 mot of amino acid 
Aspartic  acid  +  as-  14.1 (13.4  14.8)  14.2 (13.6-15.1)  13.9 (13.5-14.4)  13.9 (13.4-14.8)  14,2 (13.5-15.2)  13.8 
paragine 
Thrconine  1.1  (I.0-1.2)  0.4 (0-1,6)  Trace  0.4 (0-1.0)  Trace  Trace 
Serine  6.2 (5.6-6.5)  6.8 (6.6-7.1)  6.8 (5.3-8.3)  5.8 (5.7-5.9)  5.9 (5.6-6.2)  9.3 
Glutamic acid + glu-  8.5 (8,0-8.9)  8.7 (8.2-9.4)  9.2 (8.7-9.8)  9.1  (8.0-9.6)  9.4 (9. I-9.8)  11.5 
tamlne 
Proline  3.8 (3.7-3.9)  3.9 (3.8-4.0)  3.6 (3.3-3.9)  3.9 (3,8-3.9)  3.8 (3.7-3.9)  3,7 
Glycine  13.0 (12.7-13.2)  12,6 (I 1.9-13.8)  13.1 (12.3-14.4)  12.4 (11.6-13.4)  12.7 (12,2-13.3)  13.3 
Alanine  14.5 (13.3-15.7)  15.1 (14.3-15.4)  15.6 (15.2-16.0)  15.4 04.9-15.7)  15.4 (14.9-15,7)  14.3 
Cysteine**  0  0  0  0  0  0 
Valine  0.9 (0.5-1.2)  0.7 (0-1.1)  0.8 (0.7-0.9)  0.9 (0.5  1.8)  0.8 (0.6-1.0)  1.5 
Met hioni ne  1.8 ( I. 7  - 1.9)  1.9 ( 1.8-2. I  )  1.7 ( 1.5~ 1.9)  1.9 ( 1.8- 1.9)  I .g ( 1.8- 1.9)  1.6 
lsoleucine  2.6 (2.3-2.8)  2.7 (2.4-3. I)  2.6 (2.5-2.6)  2.7 (2,3-3.1)  2.6 (2.2-2.8)  2.5 
Leucine  4.6 (4. I-5. I)  4.4 (4.1-4.8)  3.9 (3.8-4.2)  3.6 (3.1-4.1)  3.2  3.7 
Tyro~ine  5.3 (5.0-5.6)  4.8 (4.3-5.1)  4.7 (4.6-4.8)  4.9 (4.8-5.0)  4.9 (4.8-5.0)  4.6 
Phenylalanine  5.7 (5.4-5.9)  5.8 (5.5-6.1)  6,3 (6.0-6.7)  7.3 (5.9-7.9)  7.7 (7.5-7.9)  6.9 
Histidlne  2.8 (2.5  3.0)  2.8 (2.5-3.1)  3.2 (2.9-3.7)  2.9 (2.8-3.0)  2.9 (2.8-2.9)  3.6 
Lysine  4.5 (4.2-4.7)  4.4 (3.9-5.4)  4.2 (4.1-4.3)  4.1 (4.0-4.2)  4.1 (4.0-4.2)  4.4 
Tryptophan  1.8 (1.4-2.1)  IB (1.4-2.3)  1.5 (I.3-1.8)  1.8 (1.4-2.3)  2.1  (I.7-2.4)  0.9 
Arginine  I  1, I  (10.8-I 1.4)  10.0 (9.5-10.7)  10.0 (9.5-10.3)  10.2 (9.3-11.4)  9.9 (9.2-10,3)  7.8 
* Means (and ranges) after hydrolysis in 4 N methane sulfonic acid. 
:~ Mean of two preparations from a normal subject and a patient Waldenstr6m's macroglobulinemia. 
§ Mean of four preparations from  a normal subject and a patient with Waldenstr6m's  macroglobulinemia. 
][ Mean of three preparations from a normal subject and a patient with Waldenstr6m's macroglobulinemia. 
¶ Single determination  from a normal subject. 
** Cystelne  determined  a.s cysteic acid after performic acid oxidation  (26). 
SAA. Manual Edman degradation yielded the sequence NH2-arg-ser-phe-phe- for the 
SAA in DEAE peak 4 and NH2-ser-phe-phe- for the protein in peak 5. 
Discussion 
Segrest  et al.  (35) predicted, from knowledge of the primary structure of AA, that 
this protein could form amphipathic helixes and possibly bind lipid. An unusual AA 
protein of 45  residues sequenced by  Ein et  al.  (36)  was then shown to form stable 
complexes with  dimyristoylphosphatidylcholine  (35).  These  observations prompted 
Benditt and Eriksen  (13) to search for SAA among the plasma lipoproteins. In studies 
of SAA in the plasma of a typhoid-immunized woman they found only -2% of the 
SAA immunoreactivity  in  the fraction  of density <  1.12  g/ml,  which  includes  the 
very-low density,  low density,  and HDL2 classes  of lipoproteins.  About 57% of the 
SAA was in the HDL2 subfraction  (1.12 <  density <  1.21 g/ml),  17% in a zone of 
slightly higher density, and 15% was recovered with the bulk of serum proteins in the 
infranatant fraction (density >  1.21 g/ml). 
Recognition that SAA is transported in association with HDL greatly facilitated its 
purification.  Most  potentially  contaminating  plasma  proteins  were  removed  by 
preparative  ultracentrifugation.  SAA proved to be of lower molecular weight  than 
the major HDL apoproteins, and the latter were separated from SAA by molecular- 
sieve chromatography.  DEAE cellulose chromatography in  urea-containing buffers 
permitted isolation of relatively homogeneous preparations of six polymorphic forms 
of SAA. Identity of these proteins with SAA is supported both by an immunoassay 
employing AA standards and antiserum to AA, and by the amino acid compositions 
(Table I), which are very similar to those reported by others (9, 11, 12). These proteins, L.  L.  BAUSSERMAN, P.  N.  HERBERT, AND K.  P.  W. J.  McADAM  651 
moreover,  have  amino  acid  compositions  very  similar  to  two  threonine-poor  apo 
isolated by Shore et al,  (37)  from the sera of two men with coccidioidomycosis. One 
of the threonine-poor apo had an apparent molecular weight of 40,000 and dissociated 
into  Mr  -  22,000  subunits  after  mercaptoethanol  treatment.  The  other,  of nearly 
identical  amino acid composition, had an  11,000  mol wt. These investigators attrib- 
uted the enrichment of HDL with these proteins to amphotericin B treatment, but it 
would  appear probable  that  they  represent  SAA.  However, we  have  not  observed 
dimeric  forms of SAA,  and  none  of the  polymorphic  forms reported  here  contain 
cysteine. 
The SAA heterogeneity we have documented cannot be attributed  to large differ- 
ences  in  molecular weight,  and  carbohydration  does not  appear to account  for  the 
polymorphism. Variability at  the COOH-terminals of the  SAA proteins is  unlikely 
because all six forms isolated had COOH-terminal tyrosine.  Sufficient  quantities of 
the  major  SAA  species,  SAA4  and  SAA5  (Fig.  7),  were  available  for NH2-terminal 
residue analyses. SAA~,  unlike SAA4,  lacked the NH2-terminal arginine residue. The 
NH~-terminal sequence  NH2-arg-ser-phe-phe- has been  reported  for both AA  (1,  2, 
36,  38)  and  SAA  (11,  12). Levin et  al.  (1),  however, noted  that  serine,  rather  than 
arginine, was the principal NH2-terminal residue identified in AA from a patient with 
familial Mediterranean  fever, whereas only small amounts of arginine were present. 
Rosenthal  et  al.  (11)  found  NHz-terminal heterogeneity  in  their  SAA  preparation, 
whereas Anders et al.  (12)  reported that  40% of an SAA preparation  they analyzed 
did not have NH2-terminal arginine. 
Fie.  7.  Designation of the polymorphic forms of SAA identified by polyacrylamide gel electro- 
phoresis and isolated by DEAE-cellulose  chromatography (Fig. 6). Apo "D-2" (33) and C-III-2 are 
also visualized in  this low molecular weight fraction from the  apo  HDL of the  patient  with 
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TABLE II 
Comparison of the Amino Acid Contents of SAA and AA 
SAA~  AA*  Fragment 
cleaved 
Aspartic acid/asparagine  (15.1)  15~:  10  5 
Threonine  (0.4)  0-1  1  0 
Serine  (6.3)  6  6  0 
Glutamic acid/glutamine  (9.9)  10  6  4 
Proline  (4.2)  4  1  3 
Glycine  (13.47)  13  9  4 
Alanine  (16.7)  17  12  5 
Cysteine  (0)  0  0  0 
Valine  ( 1.0)  1  1  0 
Methionine  (2.0)  2  2  0 
Isoleucine  (3.0)  3  3  0 
Leucine  (3.9)  4  2  2 
Tyrosine  (5.3)  5  4  1 
Phenylalanine  (7.9)  8  5  3 
Histidine  (3.2)  3  1  2 
Lysine  (4.45)  4  2  2 
Tryptophan  (2.0)  2  1  1 
Arginine  (11.0)  11  10  1 
Total residues  109  76  33 
* Calculated assuming a single valine. 
:l: From Levin et al. (I). 
The  absence  of an  arginine  residue  from  SAA4 could  account  for  the  different 
electrophoretic mobilities of SAAa and SAA5 (Fig. 7).  It is unlikely, however, that all 
SAA charge heterogeneity documented is attributable to NH2-terminal differences. If 
the  low  electrophoretic  mobility  of SAA1  relative  to  SAA5 were  a  result  of NH2- 
terminal differences, then SAA1 would be expected to contain about five more lysine 
(pK~ ~  9.4-10.6)  or arginine  (pKa ~  12.5)  residues  in the NH2-terminal  region. The 
amino acid compositions of SAA1 and SAA5 (Table I) do not support the contention 
that such differences in basic amino acid contents exist. Deamidation of glutamine or 
asparagine residues during purification is similarly unlikely. SAA1 is soluble in acidic, 
rather than basic, buffers, and prolonged storage in 0.1  N  acetic acid has not altered 
its electrophoretic  mobility.  Moreover, artifactual  polymorphism  from deamidation 
has not been produced in other apo simultaneously purified. 
The possibility that SAA microheterogeneity reflects different cellular origins of the 
proteins, and perhaps varying degrees of posttranslational  modification (39), remains 
to be tested.  Rosenthal  and Sullivan  (40)  have provided evidence for a  polymorpho- 
nuclear  leukocyte origin of SAA, and synthesis by connective tissue  and  fibroblasts 
has  been  suggested  (41).  It  has  also  been  argued  from  the  time-course  of  SAA 
appearance and tissue distribution  that the liver is capable of SAA synthesis (42, 43). 
Selinger et al.  (44)  have recently demonstrated that SAA can be synthesized in vitro 
by isolated  mouse hepatocytes. This SAA synthesis was induced by a  soluble  factor 
derived  from stimulated  macrophages,  which  suggests  that  there  is  immunological 
control  of the  hepatic  synthesis  of this  apo.  Gorevic  et  al.  (45),  moreover,  have 
provided  evidence  that  murine  AA  and  SAA  are  polymorphic,  thus  raising  the 
possibility that the SAA heterogeneity may be a  tissue-specific phenomenon. L. L. BAUSSERMAN, P. N.  HERBERT, AND K. P. W. J.  McADAM  653 
Assuming an  11,000-12,000  tool wt, we have calculated that SAA contains -109 
residues  (Table  II).  If SAA and AA are related as  precursor and product, then a 
peptide  of ~33  residues  must  be  specifically  cleaved  from  SAA  before  its  tissue 
deposition. It might be speculated that AA is protected from more extensive proteolysis 
because of its lipoprotein association,  but it is noteworthy that a protein identical to 
AA has not yet been identified among the low molecular weight proteins of HDL. 
The plasma residence  time of the SAA apoproteins, as judged from the response  of 
the normals injected with etiocholanolone (15), is considerably less than that of apo 
A-I  and apo A-II but  may not  differ greatly from that  of the C-apo  (46). Thus, 
whereas the rapid turnover of SAA may be related to biological  properties not yet 
defined, the possibility that SAA proteins are normally catabolized like other apo will 
warrant investigation. 
Summary 
Serum amyloid A proteins  (SAA), presumed precursors  of the tissue  amyloid A 
proteins (AA) characteristic of secondary amyloidosis, have been isolated from the 
plasma high-density lipoproteins  (HDL)  of normals after etiocholanolone-induced 
inflammation and  from  patients  with  Wegener's  granulomatosis, systemic  lupus 
erythematosis,  juvenile rheumatoid arthritis, WaldenstriSm's macroglobulinemia, and 
Goodpasture's syndrome. At  least  six  polymorphic forms  of SAA  were  identified 
among the low molecular weight proteins of HDL, and these comprised up to 27% of 
the total HDL protein. Gel and ion-exchange chromatography permitted isolation of 
the SAA polymorphs in homogeneous form. Their amino acid compositions were very 
similar, they were indistinguishable in cationic and sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis  systems, and each had the terminal sequence COOH-Tyr- 
Lys-Phe-. Charge heterogeneity in anionic-urea polyacrylamide  gel electropherograms 
was  unaffected by neuraminidase treatment, and none of the SAA  protein bands 
stained with the periodate-Schiff reagent. 
The two major SAA polymorphs, designated SAA4 and SAA~ according to their 
order of elution from DEAE-cellulose, had different NH2-terminal sequences. Manual 
Edman degradation demonstrated NH2-arg-ser-phe-phe-  for SAA4 and NH2-ser-phe- 
phe- for SAAs. This NH2-terminal heterogeneity corresponds  to that most frequently 
reported  for AA and suggests  that  microheterogeneity in  SAA  may underlie that 
already documented in AA. Sufficient quantities of the other SAA polymorphs were 
not available for similar analyses, but the amino acid compositions do not indicate 
that  NH2-terminal  heterogeneity accounts  for  all  of the  observed  polymorphism. 
Artifactual polymorphism also appears unlikely, and the heterogeneity of SAA may 
reflect origin from more than one cell type with or without posttranslational modifi- 
cation. 
We calculate from quantitative COOH-terminal analyses that SAA is of 11,000- 
11,900 tool wt. Primary structure studies have shown AA to be a single chain protein 
of 76 residues, and SAA, therefore, appears to contain a peptide of 33 amino acids 
that is missing from AA. 
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